Health Check: Amplia shares surge on pancreatic cancer trial results; Immutep offers hope

Leveraging the power of data to improve pancreatic cancer treatment

Jakob Kirkegård is a physician, associate professor, and now also a doctor at Aarhus University's Department of Clinical Medicine and Aarhus University Hospital. He has just obtained his doctoral degree in the surgical treatment of pancreatic cancer – one of the most deadly forms of cancer.

Health Check: Amplia shares surge on pancreatic cancer trial results; Immutep offers hope

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteoarthritis trial   Given it’s National Palliative Care Week, it’s apt that two drug developers have posted hopeful trial updates pertaining to two of the most deadly cancers. Amplia (ASX:ATX) reports the latest …

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to…